PA
PRCT icon

Parallel Advisors’s Procept Biorobotics PRCT Stock Holding History

Parallel Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.4K Sell
2,409
-541
-18% -$13.5K ﹤0.01% 2081
2026
Q1 		$73.8K Buy
2,950
+2,409
+445% +$67.9K ﹤0.01% 1764
2025
Q4 		$17K Sell
541
-410
-43% -$13.6K ﹤0.01% 2374
2025
Q3 		$33.9K Sell
951
-59
-6% -$2.69K ﹤0.01% 1994
2025
Q2 		$58.2K Sell
1,010
-10
-1% -$565 ﹤0.01% 1638
2025
Q1 		$59.4K Buy
1,020
+4
+0.4% +$273 ﹤0.01% 1535
2024
Q4 		$81.8K Buy
1,016
+439
+76% +$37.5K ﹤0.01% 1371
2024
Q3 		$46.2K Buy
577
+77
+15% +$5.47K ﹤0.01% 1673
2024
Q2 		$30.5K Buy
500
+20
+4% +$1.19K ﹤0.01% 1765
2024
Q1 		$23.7K Hold
480
– – ﹤0.01% 1890
2023
Q4 		$20.1K Buy
+480
New +$16.3K ﹤0.01% 1939

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parallel Advisors's PRCT Position: Q2 2026 in Review

Parallel Advisors reduced its Procept Biorobotics (PRCT) stake by 18% in Q2 2026, selling an estimated $13.5K and leaving 2,409 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Parallel Advisors first reported a position in PRCT in Q4 2023 and has held it in 11 quarters since. The position peaked at $81.8K in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Parallel Advisors held 2,409 shares of Procept Biorobotics worth $54.4K as of Q2 2026.
  • Parallel Advisors sold 541 Procept Biorobotics shares in Q2 2026, an estimated $13.5K.
  • Procept Biorobotics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2081 holding.
  • Parallel Advisors first reported a position in Procept Biorobotics in Q4 2023 and has held it in 11 quarters since.
  • Parallel Advisors's Procept Biorobotics position peaked at $81.8K in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.